| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Alitretinoin | hsa00310 | Lysine degradation | 4.97E-02 | 2 | Q9NVH6, O15047 | TMLHE, SETD1A | More | | | Alitretinoin | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Alitretinoin | hsa00520 | Amino sugar and nucleotide sugar metabolism | 7.87E-03 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | | Alitretinoin | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 2.03E-02 | 1 | Q9Y2C2 | UST | More | | | Alitretinoin | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Alitretinoin | hsa00561 | Glycerolipid metabolism | 7.73E-03 | 3 | Q8NEB5, P14550, Q86XP1 | PPAPDC1B, AKR1A1, DGKH | More | | | Alitretinoin | hsa00591 | Linoleic acid metabolism | 4.96E-02 | 1 | P11712 | CYP2C9 | More | | | Alitretinoin | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 4.30E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | | Alitretinoin | hsa00620 | Pyruvate metabolism | 4.97E-02 | 2 | P40926, P14550 | MDH2, AKR1A1 | More | | | Alitretinoin | hsa00900 | Terpenoid backbone biosynthesis | 3.03E-03 | 1 | Q9UHG3 | PCYOX1 | More | | | Alitretinoin | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | | Alitretinoin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.03E-03 | 1 | Q16772 | GSTA3 | More | | | Alitretinoin | hsa00982 | Drug metabolism - cytochrome P450 | 3.03E-03 | 1 | Q16772 | GSTA3 | More | | | Alitretinoin | hsa00983 | Drug metabolism - other enzymes | 2.64E-03 | 5 | P04183, P20839, P32320, P05164, Q16772 | TK1, IMPDH1, CDA, MPO, GSTA3 | More | | | Alitretinoin | hsa01240 | Biosynthesis of cofactors | 3.29E-02 | 2 | P13716, P14618 | ALAD, PKM2 | More | | | Alitretinoin | hsa01522 | Endocrine resistance | 5.97E-03 | 4 | P14780, P22694, P10415, Q13323 | MMP9, PRKACB, BCL2, BIK | More | | | Alitretinoin | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | | Alitretinoin | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | | Alitretinoin | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | | Alitretinoin | hsa03320 | PPAR signaling pathway | 3.78E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | | Alitretinoin | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | | Alitretinoin | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | | Alitretinoin | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.65E-02 | 5 | P09341, P19875, Q13651, P14784, P01375 | CXCL1, CXCL2, IL10RA, IL2RB, TNF | More | | | Alitretinoin | hsa04062 | Chemokine signaling pathway | 9.23E-03 | 10 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | | Alitretinoin | hsa04064 | NF-kappa B signaling pathway | 5.05E-04 | 10 | P10415, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, ATM, GADD45A, CXCL1 | More | | | Alitretinoin | hsa04080 | Neuroactive ligand-receptor interaction | 4.90E-03 | 6 | P08311, Q15722, P21453, Q9H228, O00398, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, ADRB2 | More | | | Alitretinoin | hsa04114 | Oocyte meiosis | 4.51E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Alitretinoin | hsa04120 | Ubiquitin mediated proteolysis | 3.92E-02 | 4 | Q969M7, Q86TM6, Q16763, O95071 | UBE2F, SYVN1, UBE2S, UBR5 | More | | | Alitretinoin | hsa04130 | SNARE interactions in vesicular transport | 4.96E-02 | 1 | O15155 | BET1 | More | | | Alitretinoin | hsa04137 | Mitophagy - animal | 2.73E-02 | 3 | Q96CV9, Q14596, P18848 | OPTN, NBR1, ATF4 | More | | | Alitretinoin | hsa04140 | Autophagy - animal | 5.97E-03 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | | Alitretinoin | hsa04142 | Lysosome | 4.41E-02 | 2 | P10619, P49281 | CTSA, SLC11A2 | More | | | Alitretinoin | hsa04150 | mTOR signaling pathway | 1.59E-02 | 2 | P23588, P04628 | EIF4B, WNT1 | More | | | Alitretinoin | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | | Alitretinoin | hsa04210 | Apoptosis | 2.31E-02 | 8 | Q13315, P10415, P01375, P24522, Q16548, Q13077, P18848, Q14643 | ATM, BCL2, TNF, GADD45A, BCL2A1, TRAF1, ATF4, ITPR1 | More | | | Alitretinoin | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | | Alitretinoin | hsa04330 | Notch signaling pathway | 7.73E-03 | 3 | Q92542, P49768, P46531 | NCSTN, PSEN1, NOTCH1 | More | | | Alitretinoin | hsa04340 | Hedgehog signaling pathway | 1.19E-03 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | | Alitretinoin | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | | Alitretinoin | hsa04370 | VEGF signaling pathway | 2.47E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Alitretinoin | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Alitretinoin | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | | Alitretinoin | hsa04540 | Gap junction | 2.86E-02 | 3 | P22694, P68371, Q14643 | PRKACB, TUBB2C, ITPR1 | More | | | Alitretinoin | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.41E-02 | 2 | P04628, Q02535 | WNT1, ID3 | More | | | Alitretinoin | hsa04612 | Antigen processing and presentation | 5.03E-03 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Alitretinoin | hsa04613 | Neutrophil extracellular trap formation | 4.02E-02 | 9 | P05164, P08246, Q9UM07, Q15080, P20160, P08311, P49913, P21730, P21462 | MPO, ELA2, PADI4, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1 | More | | | Alitretinoin | hsa04621 | NOD-like receptor signaling pathway | 2.31E-02 | 8 | Q14643, P43490, O00463, P10415, P01375, P09341, P49913, P12838 | ITPR1, PBEF1, TRAF5, BCL2, TNF, CXCL1, CAMP, DEFA4 | More | | | Alitretinoin | hsa04622 | RIG-I-like receptor signaling pathway | 2.65E-02 | 2 | Q12933, P10145 | TRAF2, IL8 | More | | | Alitretinoin | hsa04625 | C-type lectin receptor signaling pathway | 2.81E-02 | 5 | P20749, Q9UDY8, Q14643, P01375, Q13191 | BCL3, MALT1, ITPR1, TNF, CBLB | More | | | Alitretinoin | hsa04650 | Natural killer cell mediated cytotoxicity | 2.12E-06 | 13 | P16298, P50591, P01375, P06239, O60880, P20963, Q02750, Q13241, P26718, O14931, P26717, Q07444, P26715 | PPP3CB, TNFSF10, TNF, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KLRC3, KLRC1 | More | | | Alitretinoin | hsa04657 | IL-17 signaling pathway | 4.73E-02 | 5 | O00463, P09341, P14780, P80188, P01375 | TRAF5, CXCL1, MMP9, LCN2, TNF | More | | | Alitretinoin | hsa04658 | Th1 and Th2 cell differentiation | 2.82E-06 | 10 | Q04759, P07766, P20963, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | | Alitretinoin | hsa04659 | Th17 cell differentiation | 1.91E-06 | 15 | P25963, Q04759, P19174, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | Q04759 | PRKCQ | Protein kinase C theta type | -0.794 | | P40199 | CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 | Q04759 | PRKCQ | Protein kinase C theta type | -0.897 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.76 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.788 | | P40199 | CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.78 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | Q9HBE5 | IL21R | Interleukin-21 receptor | -0.715 | | P40199 | CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 | Q9HBE5 | IL21R | Interleukin-21 receptor | -0.799 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.813 | | P40199 | CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.746 | | P40199 | CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.79 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.716 | | P31997 | CEACAM8 | Carcinoembryonic antigen-related cell adhesion molecule 8 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.904 | | P40199 | CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.818 |
| | Alitretinoin | hsa04660 | T cell receptor signaling pathway | 6.24E-05 | 10 | P01375, Q9UDY8, Q04759, O95267, Q08881, P07766, P20963, P01732, Q13191, P06239 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD8A, CBLB, LCK | More | | | Alitretinoin | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Alitretinoin | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | | Alitretinoin | hsa04668 | TNF signaling pathway | 5.03E-03 | 7 | P01375, O00463, P18848, P09341, P20749, Q13077, P14780 | TNF, TRAF5, ATF4, CXCL1, BCL3, TRAF1, MMP9 | More | | | Alitretinoin | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | | Alitretinoin | hsa04720 | Long-term potentiation | 2.35E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | | Alitretinoin | hsa04725 | Cholinergic synapse | 3.47E-03 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | | | Alitretinoin | hsa04727 | GABAergic synapse | 2.73E-02 | 3 | P63218, P50151, P28472 | GNG5, GNG10, GABRB3 | More | | | Alitretinoin | hsa04913 | Ovarian steroidogenesis | 2.72E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Alitretinoin | hsa04914 | Progesterone-mediated oocyte maturation | 7.70E-03 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | | Alitretinoin | hsa04915 | Estrogen signaling pathway | 2.07E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | | | Alitretinoin | hsa04918 | Thyroid hormone synthesis | 2.75E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | | Alitretinoin | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | | Alitretinoin | hsa04922 | Glucagon signaling pathway | 4.66E-02 | 2 | P14618, P06737 | PKM2, PYGL | More | | | Alitretinoin | hsa04924 | Renin secretion | 3.09E-03 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | | Alitretinoin | hsa04927 | Cortisol synthesis and secretion | 3.58E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | | Alitretinoin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.51E-04 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | | Alitretinoin | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.11E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | | | Alitretinoin | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | | | Alitretinoin | hsa04970 | Salivary secretion | 2.11E-02 | 3 | P07550, P22694, Q14643 | ADRB2, PRKACB, ITPR1 | More | | | Alitretinoin | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | | Alitretinoin | hsa05034 | Alcoholism | 3.50E-02 | 4 | P62873, Q93077, O60814, P68431 | GNB1, HIST1H2AC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Alitretinoin | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | | | Alitretinoin | hsa05134 | Legionellosis | 3.83E-02 | 3 | P01375, P09341, P19875 | TNF, CXCL1, CXCL2 | More | | | Alitretinoin | hsa05135 | Yersinia infection | 2.58E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | | Alitretinoin | hsa05140 | Leishmaniasis | 3.39E-02 | 3 | P11215, P42224, P29350 | ITGAM, STAT1, PTPN6 | More | | | Alitretinoin | hsa05142 | Chagas disease | 2.90E-02 | 4 | P01375, P30679, P07766, P20963 | TNF, GNA15, CD3E, CD247 | More | | | Alitretinoin | hsa05144 | Malaria | 3.83E-02 | 3 | P60033, P01375, P26718 | CD81, TNF, KLRK1 | More | | | Alitretinoin | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | | | Alitretinoin | hsa05146 | Amoebiasis | 9.40E-05 | 8 | P09341, P19875, P01375, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, TNF, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | | Alitretinoin | hsa05150 | Staphylococcus aureus infection | 1.47E-02 | 5 | P21730, P21462, P13765, P12838, P49913 | C5AR1, FPR1, HLA-DOB, DEFA4, CAMP | More | | | Alitretinoin | hsa05152 | Tuberculosis | 4.32E-02 | 6 | P48382, P01375, P10415, P13765, P49913, Q9UDY8 | RFX5, TNF, BCL2, HLA-DOB, CAMP, MALT1 | More | | | Alitretinoin | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | | Alitretinoin | hsa05170 | Human immunodeficiency virus 1 infection | 4.37E-02 | 4 | Q02750, P62879, P16298, Q05397 | MAP2K1, GNB2, PPP3CB, PTK2 | More | | | Alitretinoin | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | | Alitretinoin | hsa05202 | Transcriptional misregulation in cancer | 2.51E-02 | 10 | Q13315, P14780, Q15744, Q16548, Q13077, P05164, P12838, P08246, Q9C0K0, P24522 | ATM, MMP9, CEBPE, BCL2A1, TRAF1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | | Alitretinoin | hsa05204 | Chemical carcinogenesis | 3.03E-03 | 1 | Q16772 | GSTA3 | More | | | Alitretinoin | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | | Alitretinoin | hsa05212 | Pancreatic cancer | 4.45E-03 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | | Alitretinoin | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | | Alitretinoin | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | | Alitretinoin | hsa05225 | Hepatocellular carcinoma | 1.21E-02 | 3 | P04628, Q92922, Q9NPI1 | WNT1, SMARCC1, BRD7 | More | | | Alitretinoin | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | | Alitretinoin | hsa05310 | Asthma | 5.45E-04 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | | Alitretinoin | hsa05321 | Inflammatory bowel disease | 2.88E-06 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | | Alitretinoin | hsa05322 | Systemic lupus erythematosus | 1.98E-02 | 4 | P29965, Q93077, O60814, P68431 | CD40LG, HIST1H2AC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Alitretinoin | hsa05332 | Graft-versus-host disease | 5.67E-03 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | | Alitretinoin | hsa05418 | Fluid shear stress and atherosclerosis | 4.21E-03 | 2 | Q16772, P51636 | GSTA3, CAV2 | More | |
|
